JP2004262772A - Glycyrrhizin-containing percutaneous pharmaceutical preparation - Google Patents
Glycyrrhizin-containing percutaneous pharmaceutical preparation Download PDFInfo
- Publication number
- JP2004262772A JP2004262772A JP2003037553A JP2003037553A JP2004262772A JP 2004262772 A JP2004262772 A JP 2004262772A JP 2003037553 A JP2003037553 A JP 2003037553A JP 2003037553 A JP2003037553 A JP 2003037553A JP 2004262772 A JP2004262772 A JP 2004262772A
- Authority
- JP
- Japan
- Prior art keywords
- water
- glycyrrhizin
- aqueous solution
- treatment
- transdermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 title claims abstract description 86
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 229960004949 glycyrrhizic acid Drugs 0.000 title claims abstract description 84
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 title claims abstract description 84
- 235000019410 glycyrrhizin Nutrition 0.000 title claims abstract description 84
- 239000004378 Glycyrrhizin Substances 0.000 title claims abstract description 81
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims abstract description 27
- 239000007864 aqueous solution Substances 0.000 claims abstract description 20
- 208000034656 Contusions Diseases 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 25
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 238000009472 formulation Methods 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 229940069445 licorice extract Drugs 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 8
- 208000034526 bruise Diseases 0.000 abstract description 4
- 208000017520 skin disease Diseases 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
- 208000027418 Wounds and injury Diseases 0.000 description 19
- 206010052428 Wound Diseases 0.000 description 12
- 208000025865 Ulcer Diseases 0.000 description 10
- 231100000397 ulcer Toxicity 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000005507 spraying Methods 0.000 description 9
- 244000309464 bull Species 0.000 description 8
- 230000035876 healing Effects 0.000 description 8
- 239000007921 spray Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000015788 innate immune response Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- -1 polyoxyethylene Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000001685 glycyrrhizic acid Substances 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000006174 pH buffer Substances 0.000 description 3
- 239000003380 propellant Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006802 Burns second degree Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940074777 tripotassium glycyrrhizinate Drugs 0.000 description 2
- ZXHXYXSTAYNRLQ-DWJAGBRCSA-K tripotassium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4, Chemical compound [K+].[K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O ZXHXYXSTAYNRLQ-DWJAGBRCSA-K 0.000 description 2
- CCXAYLQLOLXXKE-DWJAGBRCSA-K trisodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-t Chemical compound [Na+].[Na+].[Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O CCXAYLQLOLXXKE-DWJAGBRCSA-K 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010003402 Arthropod sting Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018999 Haemorrhage subcutaneous Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000002436 femur neck Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000005005 intertrigo Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】
【発明の属する技術分野】
本発明はグリチルリチン含有経皮製剤に関するものであり、さらに詳しくは、本発明は、打撲傷、熱傷または褥創を治療するのに有効なグリチルリチン含有経皮製剤に関するものである。
【0002】
【従来の技術】
甘草の主成分であるグリチルリチンは、グリチルレチンと2分子のグルクロン酸との抱合体である。グリチルリチン酸とその塩(例えば、グリチルリチン酸二カリウム、グリチルリチン酸三カリウム、グリチルリチン酸二ナトリウム、グリチルリチン酸三ナトリウム、グリチルリチン酸モノアンモニウム、グリチルリチン酸二アンモニウム等)は甘味料として使用されている。グリチルリチンはまた、抗炎症作用を有し(Inoue,H.,他、Chemi.Pharm.Bull., 35,3883−3889,1987;及び、Inoue, H.,他、Chem.Pharm.Bull.,34, 897−901,1986)、生体の自然免疫を高め(清野宏:粘膜免疫における自然免疫、Molecular Medicine, 36(5), 520−526, 1999;及び熊谷勝男:Overview, 自然免疫に於ける細菌の認識機構。単稿本:炎症と免疫、2001年9月)、粘膜や皮膚を通過する物質の通過能を亢進させる能力を有する(Motohiro Mishima他、Biol.Pharma.Bull, 18(4) 566−570, 1995;及び、Wang,Z.,他、Biol.Pharm.Bull., 17,(10) 1389−1403, 1994)ことが知られている。
【0003】
皮膚疾患(例えば、火傷、創傷、一般的な手術による創傷、凍瘡、床ずれ、毛包炎、膿痂疹、間擦疹、放射線による潰瘍、尋常性座疹または湿疹様感染性皮膚炎など)は、紅斑、腫脹、水庖、びらん、または潰瘍などを生じ、細菌感染を伴うことが多い。これらの皮膚疾患を治療することを目的として、壊死組織の再生および繊維芽細胞の増殖を促進することがきる組織再生活性化剤や抗生物質を含有する局所投与製剤が開発されている。しかし、これらの製剤でも十分な治療効果が得られない場合が多い。
【0004】
例えば、患者が寝たきりになると、床ずれ(褥創)ができやすくなり、その予防や治療が難しかった。従来、そのような患者の褥瘡の治療法としては、生理食塩水、消毒液、ソアナースパスタ(イソジンシュガー軟膏、殺菌用薬剤)で処置し、褥創が治りかけると、生理食塩水、消毒液、アクトシン軟膏(褥瘡の治療効果を促進する軟膏、肉芽を増殖する薬剤)などを使用してきた。これらの方法で治療効果が得られない患者には、既存の軟膏やドレッシングを使い分けて褥瘡の治療にあたっていた。しかし、これらの方法でも十分な治療効果が得られない場合がある。また、グリチルリチンを静脈注入することにより、褥創を治療する例も報告されているが(中溝慶生 他、グリチルリチン製剤の褥創治療促進効果、臨床と研究、72巻、6号、231−234、1995)、グリチルリチンの経皮投与することにより褥創を治療することについてはこれまで全く報告がない。
【0005】
【非特許文献1】
Inoue,H.,他、Chemi.Pharm.Bull., 35,3883−3889,1987
【非特許文献2】
Inoue, H.,他、Chem.Pharm.Bull.,34, 897−901,1986
【非特許文献3】
清野宏:粘膜免疫における自然免疫、Molecular Medicine, 36(5), 520−526, 1999
【非特許文献4】
熊谷勝男:Overview, 自然免疫に於ける細菌の認識機構。単稿本:炎症と免疫、2001年9月
【非特許文献5】
Motohiro Mishima他、Biol.Pharma.Bull, 18(4) 566−570, 1995
【非特許文献6】
Wang,Z.,他、Biol.Pharm.Bull., 17,(10) 1389−1403, 1994
【非特許文献7】
中溝慶生 他、グリチルリチン製剤の褥創治療促進効果、臨床と研究、72巻、6号、231−234、1995
【0006】
【発明が解決しようとする課題】
本発明は、上記した従来技術の問題点を解決することを解決すべき課題とした。即ち、本発明は、打撲傷、熱傷または褥創などの皮膚疾患の治療及び/又は時に予防に有効な経皮製剤を提供することを解決すべき課題とした。
【0007】
【課題を解決するための手段】
本発明者らは上記課題を解決するために鋭意検討した結果、有効成分としてグリチルリチンを含有する水溶液を、打撲傷、熱傷または褥創を患う患者の幹部に噴霧して塗布することによりこれらの症状を緩和できることを見出し、本発明を完成するに至った。
【0008】
即ち、本発明によれば、有効成分としてグリチルリチンを含有する水溶液からなる経皮製剤が提供される。
好ましくは、上記水溶液はアンモニウム水を含む水溶液である。
好ましくは、上記水溶液は、溶媒を含む疎水性に転化した水溶液である。
好ましくは、溶媒はグリセリンおよびエタノールである。
【0009】
好ましくは、水溶液中のグリチルリチンの濃度は0.01から5重量%である。
好ましくは、グリチルリチンは、甘草エキスをHPLCで精製することにより得られるものである。
好ましくは、本発明の経皮製剤は、打撲傷、熱傷または褥創の治療及び/又は予防のために使用することができる。
【0010】
本発明の別の側面によれば、有効成分としてグリチルリチンを含有する水溶液からなる経皮製剤を、皮膚に経皮投与することを含む、打撲傷、熱傷または褥創を治療及び/又は予防するための方法が提供される。
【0011】
【発明の実施の形態】
以下、本発明の実施の形態について説明する。
本発明の経皮製剤は、有効成分としてグリチルリチンを含有する水溶液からなることを特徴とする。
本発明で用いるグリチルリチンは、例えば、甘草エキスをHPLCで精製することにより得ることができる(国立医薬品食品衛生研究所グリチルリチン酸標準品(Control 991)。斎藤博幸 他、Bull.Natl.Sci. 117, 195−198,1999)。具体的には、グリチルリチン酸、並びにその塩(例えば、グリチルリチン酸二カリウム、グリチルリチン酸三カリウム、グリチルリチン酸二ナトリウム、グリチルリチン酸三ナトリウム、グリチルリチン酸モノアンモニウム、グリチルリチン酸二アンモニウムなど)を使用することができる。
【0012】
水溶液中のグリチルリチンの濃度は所望の薬効が達成できる限り特に限定されないが、一般的には0.01から5重量%であり、好ましくは0.05から1重量%である濃度が低すぎると、有効成分であるグリチルリチンの薬効を十分に発揮することが難しく、一方、濃度が必要以上に高すぎても、配合量の増加に見合った効果の増強を達成することが困難となる。
【0013】
本発明の経皮製剤を調製するために用いる水は、通常の医薬品の分野において用いられる水であればよく、特に限定されない。
水は、本発明の経皮製剤に含まれる他の必須成分並びに任意添加成分の総配合量の残量分だけ配合することができる。本発明では、70〜99重量%程度が好ましく、特には75〜99重量%程度である。
【0014】
好ましくは、本発明の経皮製剤には、グリチルリチンの水への可溶化のために少量のアンモニウム水を添加することができる。アンモニウム水の添加量はグリチルリチンの水への可溶化を達成できる程度であればよく、一般的には水溶液全体量に対して、0〜1.0重量%程度である。
【0015】
さらに好ましくは、本発明の経皮製剤では、グリチルリチン水溶液の皮膚通過性を高めるために、グリチルリチン水溶液に溶媒を添加して疎水性に転化することができる。ここで用いる溶媒としてはアルコールを使用することができる、具体的には、グリセリンなどの多価アルコール及び一価の低級アルコール(例えば、メタノール、エタノール、ノルマルプロパノール、イソプロパノール、ノルマルブタノール、t−ブチルアルコール等)などを使用することができる。これらは1種を単独で使用してもよいし、2種以上を混合して用いることもできる。好ましくは、グリセリンとエタノールを組み合わせて使用することができる。アルコールなどの溶媒の含有量(2種以上のアルコールを使用する場合には合計の含有量)は特に限定されないが、好ましくは1〜30重量%程度であり、特に好ましくは10〜30重量%程度である。一例としては、グリチルリチン水溶液に対してグリセリンを19.3重量%、エタノールを6.1重量%になるように添加することができる。
【0016】
本発明の皮膚外用剤には、本発明の効果を妨げない限り、上記成分に加えて通常製剤化において配合されるpH緩衝剤、界面活性剤、糖類、溶解補助剤、キレート剤、防腐剤、清涼化剤、増粘剤又はゲル化剤等の添加剤を配合することができる。
【0017】
具体的には、pH緩衝剤としては、例えばホウ酸、リン酸水素ナトリウム、氷酢酸、クエン酸、水酸化ナトリウム、トリエタノールアミン、アスコルビン酸、グリシン、L−アルギニン、安息香酸、安息香酸ナトリウム、塩化ナトリウム、ブドウ糖等を使用することができる。
【0018】
界面活性剤としては、ポリオキシエチレン硬化ヒマシ油60,自己乳化型モノステアリン酸グリセリン等を使用することができ、糖類としては、マンニトール等を使用することができ、溶解補助剤としては、β−シクロデキストリン等のシクロデキストリン類,プロピレングリコール等などを使用することができ、キレート剤としてエデト酸ナトリウム等を使用することができる。
【0019】
また、防腐剤としてはエタノール,塩化ベンザルコニウム,ソルビン酸等を使用することができ、清涼化剤としてはd−カンフル,ケイヒ油,l−メントール等を使用することができ、増粘剤又はゲル化剤としてカルボキシビニルポリマー,グリセリンモノオレエート等を使用することができる。
【0020】
ここで、本発明の皮膚外用剤は、その剤型が特に制限されるものではなく、油性製剤、エマルション製剤、エアゾール製剤等として調製することもできるが、水性製剤として調製することが望ましく、例えばゲル剤,ローション剤,パップ剤等として調製すると効果的である。
【0021】
上記した必須成分及び任意成分を用いて本発明の経皮製剤を製造するためには、通常の方法を用いて行えばよく、例えば、これら成分を秤量し、必要に応じて加熱撹拌して水に溶解させた後、冷却するなどの操作により本発明の経皮製剤を製造することができる。
【0022】
本発明の経皮製剤の剤形は経皮投与に適した形態であれば特に限定されず、任意の形態に製剤化することができる。本発明の経皮製剤は、例えば、噴霧剤、ゲル剤、ローション剤、パップ剤等に調製することができ、その調製方法は、各製剤の常法によって調製することができる。
【0023】
具体的には、噴霧剤であれば、噴射剤と組み合わせることによってスプレーなどのエアゾール形態に調製することができる。噴射剤の例としては、フロン11、フロン12、フロン21、フロン113、フロン114又はフロン134a等のフロンガス、プロパン、ブタン、イソブタン、ノルマルブタン、イソペンタン又はノルマルペンタン等の炭化水素系ガス、ジメチルエーテル等の液化ガス、炭酸ガスまたは窒素ガスなどを用いることができる。
【0024】
ゲル剤であれば、例えばグリチルリチン、並びにその他の任意成分を精製水に順次添加、溶解し、得られた溶液に更に精製水を加えて各成分を所望の濃度に調整すると共に、所望によりpH緩衝剤によって製剤のpHが所望のpHとなるように最終調整した後、ゲル化剤を添加してゲル化させることによってゲル剤を得ることができる。
【0025】
ローション剤であれば、例えばグリチルリチン、並びにその他の任意成分を精製水に順次添加、溶解し、得られた溶液に更に精製水を加えて各成分を所望の濃度に調整すると共に、所望によりpH緩衝剤によって製剤のpHが所望のpHとなるように最終調整することによってローション剤を得ることができる。
【0026】
パップ剤であれば、例えばグリチルリチン、並びにその他の任意成分を精製水に順次添加、溶解し、適宜時間混練し、必要に応じてpHを最終調整した後、展延機等を用いて不織布等の支持体に一定の厚さとなるように展延し、表面を必要に応じてプラスチックフィルム等で覆った後、必要に応じて適宜大きさに裁断してパップ剤を得る方法等を挙げることができる。
【0027】
本発明の経皮製剤の使用量及び用法は特に制限されるものではなく、疾患の種類や重篤度、投与形態、患者の年齢や体重などの条件を含む種々の要因により適宜設定することができる。一般的には、有効成分であるグリチルリチンの投与量として一日当り10〜50μg/kg程度であり、好ましくは、10〜20μg/kg程度であるが、多少の増量は構わない。上記投与量の薬剤を一日1〜4回程度に分けて投与することが好ましい。
【0028】
本発明の経皮製剤は、例えば、打撲傷、熱傷または褥創の治療及び/又は予防のために使用することができ、さらに蛇による咬傷(特に蛇の種類が判らず抗血清を選択できない時)、並びに、蜂による刺傷などの治療にも使用することができる。
以下の実施例により本発明をさらに具体的に説明するが、本発明は実施例によって限定されるものではない。
【0029】
【実施例】
以下の実施例で用いたグリチルリチン(GL)水は以下の通り作製したものである。
(0.2%GL水の作り方)
グリチルリチン40mgに精製水19ml+930μlおよび2.8%アンモニウム70μlを加え、完全に溶けるまで良く混ぜる。
【0030】
実施例1:打撲傷をグリチルリチン(GL)水で治療した症例
日常生活で手足に軽い打撲傷を負ったり、軽い熱傷を負うことは誰でも経験することである、それに対してGL水を噴霧すると、GLの抗炎症作用が作動し、治療効果が現れる。
右手の手背を打撲した(第二指の指根骨部に)77才男性患者において、劇痛及び腫脹が示され、手背部に肉眼で判る腫脹と皮下出血が認められた。受傷の4分後、治療としてGL水を受傷部に噴霧し始め、4から5分ごとに、噴霧とその後の塗布を繰り返した。すなわち、左手指で患部表面に噴霧されたGL水を患部の表面に拡げ塗布した。30分経過後に、腫脹は殆どなくなり、痛みも完治した。
【0031】
この治検は健康人を対照として再現できる条件であったので、反対側の左手指を用いて対照実験を患者の許可を得て試みた。前回より症状が軽かったが相似の打撲傷を作ることができた。PBS液(緩衝液)をGL水の投与に代えて対照薬剤として噴霧、塗布した。対照の痛みと腫脹は30分の短時間では到底消えず、2日後もなお炎症症状が続き、5日目で皮下出血の跡を残して大体治癒した。
【0032】
以上のGL水群と対照であるPBS群との比較では、GL群の全治までの所用時間は35分であり、それに対して対照群は120時間でありその差は明瞭であった。即ち、GL水は打撲傷に有効であることが実証された。
各種のスポーツで用いられる打撲後のクーリング法と違い正常の体温下で、GLの抗炎症効果と沈痛効果が生理的環境下で機能した結果であると考えられる。GL水は、スポーツ界での後遺症を残さない良い鎮痛剤としても期待される。
【0033】
実施例2:第2度熱傷(熱傷性水泡)をGL水で治癒した例
前述の打撲傷と同じように、小さい熱傷(紅斑程度の軽い熱傷)はGL水の2から3回の噴霧と塗布で簡易に治癒した。これらの軽症例とは別に、水泡を伴う熱傷が、GLの噴霧塗布で水泡が縮小し、完治した。これら3例の熱傷を以下に記載する。
【0034】
(1) 男性(77才)の左第2指と第3指との間に誤って熱湯をかけた。
受傷後直ちに受傷した手を水に入れて冷やしたが、1から2分の間に受傷部に紅斑が出現し炎症が始まり、症状が進行した。そこで手を水から出して水を良く拭き取り、なお観察を続けた。続いて、第1指とその遠側の第2指側に、比較的大きな小豆大の水泡が出現してきた。この時点でGL水の受傷皮膚(水泡の直上)への噴霧と塗布を開始した(受傷後4分後)。すると、ほんの1分後に水泡の増大が止まり、逆転して縮小に転じた。ほんの1分で水泡が消失し、次の1分弱で紅斑に転じた。そしてGL水投与後10分以内で総ての炎症病変が肉眼的に完全に消えた。翌日、昨日の水泡部に紅斑が再び、かすかに生じたが再度のGL水の噴霧により病変は消失した。水泡膜の剥離も無かった。上記の通り、GL水は、熱傷性水泡に対して速効性効果を示した。
【0035】
(2) 夜6時半に女性(57才)の右手の第2指と第3指の間に熱湯を誤って掛け、指根部に熱傷を受けた。受傷後15分で水泡が生じ。まもなく大豆大で完成した。その1時間後にGL水を水泡部に噴霧、塗布したところ、4から5分間で水泡が収縮し完全に消失した。翌日水泡は識別できなかったが、GL水の噴霧を1回だけ追加した。そして受傷後6日目、水泡の痕の皮膚が治っていたので、患者はその存在を自覚しなかったが、痛みも無く水泡の膜が剥がれ全治した。一般的に水泡の皮膚が剥がれる時はヒリヒリ痛く不快な3から4日間を経験するものであるが、それが全くなく、無痛で全治した。
【0036】
(3) 朝6時、女性(52才)は左第1指と2指の間に高温の油による火傷を受傷した。数分で水泡が出現した。患部をガーゼで抑えていたが、痛みがひどく、受傷後、約2時間にGL水を噴霧および塗布した。GL水噴霧後、直ちに水泡は萎縮し始めた。さらに1時間後2回目の噴霧を行った時には水泡は完全に消えていたが、夜6時半、受傷後12時間半で最後の噴霧を行い、完治を確認した。
【0037】
実施例3:褥創をGL水で治癒した例
患者の身体的バックグランドが非常に悪く、難治性であった腸骨部の褥創を、GL水の噴霧、塗布で短時間にきれいに治癒させた症例を述べる。
2度の脳梗塞の既往を持つ高度の脳血管性痴呆の女性患者(93歳)(ランクC24、介護度4である)で試験した。この患者が、重症な潰瘍を伴う褥創に罹患した。潰瘍の拡大、悪化があり、また、一度は快方に向かい肉芽新生も認められたが、再び潰瘍が拡大した。このような経過を繰り返して全身状態が悪くなり褥創も悪化を繰り返していた(図1の(1)、GL水で毎日1日2回、処理して4日目の写真)。この患者に対する、GL水による傷面処置の概要を以下に記載する。
【0038】
傷面を生理的食塩水で洗浄し、そこにGL水を広範に噴霧し、続いて噴霧が塗布になるように傷の表面についたGLの小水滴を滅菌ガーゼで拡げて傷面に塗布し、そのガーゼで傷面をカバーし、処置を終えた。毎日二回ずつ25日間に渡って(合計50回)、GL水を噴霧し塗布した。
【0039】
治癒の模様を段階的に述べる。最初の1週間は、中心部の潰瘍面が縮小し(写図1の(2))、逆に周囲の肉芽層域が拡大し傷面は乾燥した(図1の(2)および(3))。全治療行程1ヶ月弱で急速に治癒に向かった(図1の(4))。25日後にGL水の噴霧を中止した理由は、治癒が完了して、治療の必要がなくなったためである。治療中止の4日目に、褥創は完全に治癒した(図1の(5))。
【0040】
比較例1:褥創治療に対する比較例
実施例3と同一の患者においてGL水を用いなかった過去の状況を比較例として記載する。
当該患者は右大腿骨頚部骨折を受傷し、その後、右臀部に5×5cm(壊死部分と潰瘍部分よりなる)の褥創が発生した。その後、皮膚科医の指導あるいは直接の治療(アズノール、エルタシン軟膏の貼付など)を受けたが、前記の通り遷延または増悪するのみで治癒しなかった。
この状況と、前述のGL水による治療後との差は明白であった。GL水が持つ潰瘍治癒活性と、fibroblast growth factor分泌活性が前述の抗炎症作用に加わり、褥創を治癒をしたものである。
【0041】
実施例4:ラットにおける熱傷浮腫に対するGL水の治療効果
実施例2に記載したヒトでの熱傷治療活性を動物で実証した。
ラットの右後肢を70℃の熱湯に5秒間浸し、出現した足浮腫の腫脹の容積を測定した。具体的には、ラットの右後肢の一定の部位に油性黒フェルトペンを用いて印をつけ、小さな水槽内に印まで浸漬し、上昇した水の量(重量)を測定した。測定は、起炎前および起炎1、3、5時間後に実施した。結果を図2に示す。その結果、起炎のピークと考えられる5時間後においてGL水群は対照群(PBS群)と比較してはっきりした減少が認められた。各測定点でラット3頭を使い、同じ実験を2度試みたので、図2では、各点で6頭ずつのラットを用いた。なお、ラットの足の皮膚はヒトの場合と比較して明らかに厚く且つ硬いので皮膚へのGL水の透過性および他の物質の透過性を促進させる能力が、ヒトの場合と比較して効果を上げ難かったと考えられる。
【0042】
実施例5:口唇ヘルペスに対するGL水の治療効果
口唇ヘルペスが発病した時、GL水を早めに局所に噴霧し、少なくとも5から6回試みた。ヘルペスの丘疹はその日の内に萎縮し、翌日は治癒に向かう。この局所治療を実施することにより、全身性の症状は出現せず回復する症例が2ないし3例あった。この様な症例では、数年間ヘルペスの丘疹も全身症状もでなくなる。即ち、GL水による局所療法により、全身症状を完治させたと考えられる症例が認められる。
【0043】
上記したGL水の効用は、グリチルリチンの抗炎症作用、自然免疫亢進作用および抗ウイルス作用などの総合的作用によるものと推察される。グリチルリチンが粘膜を通過することは既知である。その際、粘膜の表面に存在する種々の抗原物質もグリチルリチンと共に体内に入る外来物質として生体の幾つかの非特異的防御機構を刺激および活性化し、侵入ウイルスや細菌などの病原体を非特異的に攻撃している可能性がある。
【0044】
【発明の効果】
本発明の経皮製剤は、打撲傷、熱傷または褥創の治療及び/又は予防のための薬剤として有用であり、特に噴霧剤、ゲル剤,ローション剤,パップ剤等の水性経皮製剤として有用である。
【図面の簡単な説明】
【図1】図1は、褥創をGL水で治癒した例の結果を示す。
(1):治療4日:GL水で毎日1日2回、処理して4日目の様子
(2)治療10日:最初の1週間は、中心部の潰瘍面が縮小した。
(3)治療15日:周囲の肉芽層域が拡大し傷面は乾燥した。
(4)治療22日:全治療工程1ヶ月弱で急速に治癒に向かった。25日後にGL水の噴霧を中止した。治癒が完了して、治療の必要がなくなったためである。
(5)治療31日:治療中止の4日目に、褥創は完全に治癒した。
【図2】図2は、ラットにおける熱傷浮腫に対するGL水の治療効果を示す。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a glycyrrhizin-containing transdermal formulation, and more particularly, the present invention relates to a glycyrrhizin-containing transdermal formulation that is effective for treating bruises, burns or pressure sores.
[0002]
[Prior art]
Glycyrrhizin, a main component of licorice, is a conjugate of glycyrrhetin and two molecules of glucuronic acid. Glycyrrhizic acid and its salts (eg, dipotassium glycyrrhizinate, tripotassium glycyrrhizinate, disodium glycyrrhizinate, trisodium glycyrrhizinate, monoammonium glycyrrhizinate, diammonium glycyrrhizinate, etc.) are used as sweeteners. Glycyrrhizin also has an anti-inflammatory effect (Inoue, H., et al., Chemi. Pharm. Bull., 35 , 3883-3889, 1987; and Inoue, H., et al., Chem. Pharm. Bull., 34 . , 897-901, 1986), and enhances the innate immunity of the living body (Hiroshi Seino: Innate immunity in mucosal immunity, Molecular Medicine, 36 (5), 520-526, 1999; and Katsuo Kumagai: Overview, bacteria in innate immunity). Single copy: Inflammation and immunity, September 2001), which has the ability to enhance the ability of substances to pass through mucous membranes and skin (Motohiro Mishima et al., Biol. Pharma. Bull, 18 (4) 566). -570, 1995; and Wang, Z., et al., Bio. .Pharm.Bull., 17, (10) 1389-1403, 1994) it is known.
[0003]
Skin disorders (eg, burns, wounds, general surgical wounds, erythema, bedsores, folliculitis, impetigo, intertrigo, radiation ulcers, acne vulgaris or eczema-like infectious dermatitis) Erythema, swelling, blisters, erosions, or ulcers, often accompanied by bacterial infection. For the purpose of treating these skin diseases, topical preparations containing an activator of tissue regeneration and an antibiotic capable of promoting the regeneration of necrotic tissue and the proliferation of fibroblasts have been developed. However, these preparations often fail to provide a sufficient therapeutic effect.
[0004]
For example, when a patient becomes bedridden, bedsores (pressure sores) are more likely to occur, and its prevention and treatment have been difficult. Conventionally, treatment of pressure ulcers in such patients includes treatment with physiological saline, disinfectant, and sonar paste (isodin sugar ointment, disinfectant). And Actosin ointment (an ointment that promotes the therapeutic effect of pressure ulcers, a drug that promotes granulation) and the like. For patients who did not benefit from these treatments, they used existing ointments and dressings to treat pressure ulcers. However, these methods may not provide a sufficient therapeutic effect. In addition, there have been reports of cases of treating pressure sores by intravenous injection of glycyrrhizin (Yoshio Nakamizo et al., Effect of glycyrrhizin preparation on treatment of sores, Clinical and Research, Vol. 72, No. 6, 231-234, 1995), there has been no report on treating pressure sores by transdermal administration of glycyrrhizin.
[0005]
[Non-patent document 1]
Inoue, H .; , Et al., Chemi. Pharm. Bull. , 35 , 3883-3889, 1987.
[Non-patent document 2]
Inoue, H .; Chem. Pharm. Bull. , 34 , 897-901, 1986.
[Non-Patent Document 3]
Hiroshi Kiyono: Innate Immunity in Mucosal Immunity, Molecular Medicine, 36 (5), 520-526, 1999
[Non-patent document 4]
Katsuo Kumagai: Overview, Bacterial recognition mechanism in innate immunity. Single manuscript: Inflammation and immunity, September 2001 [Non-Patent Document 5]
Motohiro Mishima et al., Biol. Pharma. Bull, 18 (4) 566-570, 1995.
[Non-Patent Document 6]
Wang, Z .; Biol. Pharm. Bull. , 17, (10) 1384-1403, 1994.
[Non-Patent Document 7]
Yoshio Nakamizo et al., Effect of glycyrrhizin preparation on treatment of pressure sore wounds, Clinical and research, Vol. 72, No. 6, 231-234, 1995
[0006]
[Problems to be solved by the invention]
An object of the present invention is to solve the above-mentioned problems of the conventional technology. That is, an object of the present invention is to provide a transdermal preparation which is effective for treating and / or sometimes preventing skin diseases such as bruises, burns or pressure sores.
[0007]
[Means for Solving the Problems]
The present inventors have conducted intensive studies to solve the above problems, and as a result, spraying and applying an aqueous solution containing glycyrrhizin as an active ingredient to the trunk of a patient suffering from bruises, burns or pressure sores, has reduced these symptoms. They have found that they can be relaxed, and have completed the present invention.
[0008]
That is, according to the present invention, there is provided a transdermal preparation comprising an aqueous solution containing glycyrrhizin as an active ingredient.
Preferably, the aqueous solution is an aqueous solution containing ammonium water.
Preferably, the aqueous solution is a hydrophobically converted aqueous solution containing a solvent.
Preferably, the solvents are glycerin and ethanol.
[0009]
Preferably, the concentration of glycyrrhizin in the aqueous solution is from 0.01 to 5% by weight.
Preferably, glycyrrhizin is obtained by purifying licorice extract by HPLC.
Preferably, the transdermal formulation of the invention can be used for the treatment and / or prevention of bruises, burns or pressure sores.
[0010]
According to another aspect of the present invention, a transdermal preparation comprising an aqueous solution containing glycyrrhizin as an active ingredient is transdermally administered to the skin, for treating and / or preventing bruises, burns or pressure sores. A method is provided.
[0011]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, embodiments of the present invention will be described.
The transdermal preparation of the present invention is characterized by comprising an aqueous solution containing glycyrrhizin as an active ingredient.
Glycyrrhizin used in the present invention can be obtained, for example, by purifying licorice extract by HPLC (National Institute of Health Sciences, Glycyrrhizic Acid Standard (Control 991). Hiroyuki Saito et al., Bull. Natl. Sci. 117, 195-198, 1999). Specifically, glycyrrhizic acid and salts thereof (eg, dipotassium glycyrrhizinate, tripotassium glycyrrhizinate, disodium glycyrrhizinate, trisodium glycyrrhizinate, monoammonium glycyrrhizinate, diammonium glycyrrhizinate, etc.) can be used. it can.
[0012]
The concentration of glycyrrhizin in the aqueous solution is not particularly limited as long as the desired drug effect can be achieved, but is generally 0.01 to 5% by weight, preferably 0.05 to 1% by weight. It is difficult to sufficiently exert the medicinal effects of glycyrrhizin, which is an active ingredient. On the other hand, if the concentration is too high, it is difficult to achieve an effect that is commensurate with an increase in the amount of the compound.
[0013]
The water used for preparing the transdermal formulation of the present invention may be any water used in the field of ordinary pharmaceuticals, and is not particularly limited.
Water can be added in the remaining amount of the total amount of other essential components and optional components contained in the transdermal formulation of the present invention. In the present invention, it is preferably about 70 to 99% by weight, particularly about 75 to 99% by weight.
[0014]
Preferably, a small amount of aqueous ammonium can be added to the transdermal formulation of the present invention for solubilizing glycyrrhizin in water. The amount of ammonium water added may be such that glycyrrhizin can be solubilized in water, and is generally about 0 to 1.0% by weight based on the total amount of the aqueous solution.
[0015]
More preferably, in the transdermal formulation of the present invention, a solvent can be added to the aqueous glycyrrhizin solution to convert the aqueous glycyrrhizin solution to hydrophobic in order to enhance the skin permeability of the glycyrrhizin aqueous solution. As the solvent used herein, alcohols can be used. Specifically, polyhydric alcohols such as glycerin and monohydric lower alcohols (for example, methanol, ethanol, normal propanol, isopropanol, normal butanol, t-butyl alcohol) Etc.) can be used. These may be used alone or as a mixture of two or more. Preferably, glycerin and ethanol can be used in combination. The content of the solvent such as alcohol (the total content when two or more alcohols are used) is not particularly limited, but is preferably about 1 to 30% by weight, and particularly preferably about 10 to 30% by weight. It is. As an example, glycerin and ethanol can be added in an amount of 19.3% by weight and 6.1% by weight, respectively, based on an aqueous glycyrrhizin solution.
[0016]
The skin external preparation of the present invention includes a pH buffering agent, a surfactant, a saccharide, a solubilizing agent, a chelating agent, a preservative, which are usually added in the formulation, in addition to the above components, as long as the effects of the present invention are not hindered. Additives such as a cooling agent, a thickening agent or a gelling agent can be blended.
[0017]
Specifically, examples of the pH buffer include boric acid, sodium hydrogen phosphate, glacial acetic acid, citric acid, sodium hydroxide, triethanolamine, ascorbic acid, glycine, L-arginine, benzoic acid, sodium benzoate, Sodium chloride, glucose and the like can be used.
[0018]
As a surfactant, polyoxyethylene hydrogenated castor oil 60, self-emulsifying glyceryl monostearate, or the like can be used. As a saccharide, mannitol or the like can be used, and as a solubilizing agent, β- Cyclodextrins such as cyclodextrin, propylene glycol and the like can be used, and sodium edetate and the like can be used as a chelating agent.
[0019]
Also, ethanol, benzalkonium chloride, sorbic acid and the like can be used as a preservative, d-camphor, cauliflower oil, l-menthol and the like can be used as a refreshing agent, and a thickener or As a gelling agent, carboxyvinyl polymer, glycerin monooleate, or the like can be used.
[0020]
Here, the external preparation for skin of the present invention is not particularly limited in its dosage form, and can be prepared as an oily preparation, an emulsion preparation, an aerosol preparation, or the like, but is preferably prepared as an aqueous preparation. It is effective to prepare it as a gel, lotion, poultice, etc.
[0021]
In order to produce the transdermal preparation of the present invention using the above-mentioned essential components and optional components, a conventional method may be used.For example, these components are weighed, and if necessary, heated and stirred to obtain water. The transdermal preparation of the present invention can be produced by dissolving the same in a solution and cooling.
[0022]
The dosage form of the transdermal formulation of the present invention is not particularly limited as long as it is a form suitable for transdermal administration, and can be formulated into any form. The transdermal formulation of the present invention can be prepared into, for example, sprays, gels, lotions, cataplasms and the like, and the preparation method can be prepared by a conventional method of each formulation.
[0023]
Specifically, if it is a propellant, it can be prepared in an aerosol form such as a spray by combining with a propellant. Examples of the propellant include Freon gas such as Freon 11, Freon 12, Freon 21, Freon 113, Freon 114 or Freon 134a, hydrocarbon-based gas such as propane, butane, isobutane, normal butane, isopentane or normal pentane, and dimethyl ether. Liquefied gas, carbon dioxide gas, nitrogen gas or the like can be used.
[0024]
In the case of a gel agent, for example, glycyrrhizin and other optional components are sequentially added to and dissolved in purified water, and each component is adjusted to a desired concentration by further adding purified water to the obtained solution, and optionally, a pH buffer. After finally adjusting the pH of the preparation to a desired pH with the agent, a gelling agent can be obtained by adding a gelling agent to cause gelation.
[0025]
In the case of a lotion, for example, glycyrrhizin and other optional components are sequentially added and dissolved in purified water, and further purified water is added to the obtained solution to adjust each component to a desired concentration, and if necessary, pH buffer. A lotion can be obtained by finally adjusting the pH of the preparation to a desired pH with the agent.
[0026]
If it is a poultice, for example, glycyrrhizin, and other optional components are sequentially added to purified water, dissolved, kneaded for an appropriate period of time, and after final adjustment of the pH as necessary, a nonwoven fabric or the like using a spreading machine or the like. After spreading the support so as to have a constant thickness, covering the surface with a plastic film or the like as necessary, a method of obtaining a poultice by cutting the film to an appropriate size as necessary can be mentioned. .
[0027]
The amount and usage of the transdermal preparation of the present invention are not particularly limited, and may be appropriately set depending on various factors including conditions such as the type and severity of the disease, the dosage form, and the age and weight of the patient. it can. Generally, the dose of glycyrrhizin as an active ingredient is about 10 to 50 μg / kg per day, and preferably about 10 to 20 μg / kg per day. It is preferable to administer the above dose of the drug in about 1 to 4 times a day.
[0028]
The transdermal formulation of the present invention can be used, for example, for the treatment and / or prevention of bruises, burns or pressure sores, and furthermore, bites caused by snakes (particularly when the type of snake is unknown and antiserum cannot be selected). , As well as for treating bee stings.
The present invention will be described more specifically with reference to the following examples, but the present invention is not limited to the examples.
[0029]
【Example】
Glycyrrhizin (GL) water used in the following examples was prepared as follows.
(How to make 0.2% GL water)
To 40 mg of glycyrrhizin, add 19 ml of purified water + 930 μl and 70 μl of 2.8% ammonium, and mix well until completely dissolved.
[0030]
Example 1: A case in which a bruise was treated with glycyrrhizin (GL) water Everyone suffers a light bruise or a minor burn in daily life while spraying GL water, Activates the anti-inflammatory effect and shows a therapeutic effect.
A 77-year-old male patient who had bruised the back of his right hand (at the phalanx of the second finger) showed severe pain and swelling, with visible swelling and subcutaneous bleeding on the back of his hand. Four minutes after the injury, GL water was sprayed onto the wound as a treatment, and spraying and subsequent application were repeated every 4 to 5 minutes. That is, GL water sprayed on the affected part surface with the left finger was spread and applied on the surface of the affected part. After 30 minutes, the swelling had almost disappeared and the pain was completely healed.
[0031]
Since this trial was a condition that could be reproduced with a healthy person as a control, a control experiment was performed with the consent of the patient using the contralateral left hand. Although the symptoms were lighter than the previous time, similar bruises could be made. A PBS solution (buffer solution) was sprayed and applied as a control drug instead of administration of GL water. The pain and swelling of the control did not disappear at all in a short time of 30 minutes, and the inflammatory symptoms continued after 2 days, and were almost cured on the 5th day, with a trace of subcutaneous hemorrhage.
[0032]
In the comparison between the GL water group and the PBS group as a control, the time required for the GL group to be completely cured was 35 minutes, whereas the control group was 120 hours, and the difference was clear. That is, GL water was proved to be effective for bruises.
Unlike the cooling method after bruising used in various sports, it is considered that the anti-inflammatory effect and the pain-relieving effect of GL function under a physiological environment under normal body temperature. GL Water is also expected to be a good painkiller that does not leave any aftereffects in the sports world.
[0033]
Example 2: Example of healing a second-degree burn (burn blister) with GL water Similar to the above-mentioned bruise, a small burn (light burn like erythema) is sprayed and applied two to three times with GL water. Healed easily. Apart from these mild cases, burns accompanied by blisters were completely cured by the spray application of GL and the blisters were reduced. The three burns are described below.
[0034]
(1) A man (77 years old) accidentally poured hot water between the second and third left fingers.
Immediately after the injury, the injured hand was immersed in water and cooled, but erythema appeared at the injured area within 1 to 2 minutes, inflammation started, and the symptoms progressed. So I took my hand out of the water, wiped it off, and continued observation. Subsequently, relatively large red bean bubbles appeared on the first finger and the far second finger side. At this point, spraying and application of GL water to the injured skin (immediately above the blisters) were started (4 minutes after the injuries). Then, after only one minute, the growth of water bubbles stopped, and the water bubbles reversed and started to shrink. The blisters disappeared in just one minute and turned into erythema in the next less than a minute. All inflammatory lesions disappeared visually within 10 minutes after administration of the GL water. On the next day, erythema again and faintly appeared in the blister part yesterday, but the lesion disappeared by the second spray of GL water. There was no peeling of the water bubble film. As mentioned above, GL water showed a fast-acting effect on burn blisters.
[0035]
(2) A woman (57 years old) accidentally poured hot water between the second and third fingers of her right hand at 6:30 p.m. Blisters were formed 15 minutes after the injury. Soon completed at Soybean University. One hour later, GL water was sprayed and applied to the water bubble portion, and the water bubble shrunk and completely disappeared in 4 to 5 minutes. The next day, no blisters could be identified, but only one spray of GL water was added. On the 6th day after the injury, the skin with scars of the blisters had healed, and the patient did not recognize the presence of the blisters. Generally, when the blisters peel off, they experience a sore and unpleasant 3 to 4 days, but they are completely absent and painless.
[0036]
(3) At 6 o'clock in the morning, a woman (age 52) suffered a hot oil burn between her first and second left fingers. Water bubbles appeared within minutes. Although the affected area was kept under gauze, the pain was severe and GL water was sprayed and applied about 2 hours after the injury. Immediately after the GL water spray, the blisters began to shrink. When the second spraying was further performed one hour later, the water bubbles had completely disappeared, but the last spraying was performed at 6:30 at night and 12 and half hours after the injury, and complete healing was confirmed.
[0037]
Example 3: Case of healing the pressure sore with GL water The patient's physical background was very poor, and the intractable ulcer pressure sore was healed in a short time by spraying and applying GL water. Describe the case.
The study was performed on a female patient (93 years old) with severe cerebral vascular dementia with a history of two strokes (rank C24, care degree 4). The patient suffered a pressure sore with a severe ulcer. The ulcer was enlarged and worsened, and granulogenesis was observed once, but the ulcer expanded again. By repeating such a process, the general condition deteriorated and the pressure sore also deteriorated ((1) in FIG. 1, a photograph on the fourth day after treatment twice daily with GL water). A summary of wound treatment with GL water for this patient is described below.
[0038]
The wound surface was washed with physiological saline, and GL water was sprayed extensively on the wound surface. Then, a small droplet of GL on the wound surface was spread with sterile gauze so that the spray was applied, and applied to the wound surface. The wound was covered with the gauze and the treatment was completed. GL water was sprayed and applied twice daily for 25 days (total of 50 times).
[0039]
The healing pattern is described step by step. During the first week, the ulcer surface in the central part shrank (Fig. 1 (2)), while the surrounding granulation layer area expanded and the wound surface dried (Fig. 1 (2) and (3)). ). Healing rapidly progressed in less than one month during the entire treatment course ((4) in FIG. 1). The reason why the spraying of the GL water was stopped after 25 days was that healing was completed and treatment was no longer necessary. On the fourth day after the treatment was stopped, the pressure sore was completely healed ((5) in FIG. 1).
[0040]
Comparative Example 1: Comparative Example for Pressure Wound Treatment A past situation in which GL water was not used in the same patient as in Example 3 is described as a comparative example.
The patient was injured by a fracture of the right femoral neck, and a 5 × 5 cm (composed of a necrotic part and an ulcer part) pressure sore developed in the right hip. Thereafter, she was instructed by a dermatologist or treated directly (such as application of aznol or ertasin ointment), but as described above, it prolonged or worsened but did not cure.
The difference between this situation and the post-treatment with GL water described above was evident. The ulcer healing activity and the fibroblast growth factor secretion activity of the GL water are added to the above-mentioned anti-inflammatory effect, and heal the pressure sore.
[0041]
Example 4: Therapeutic effect of GL water on burn edema in rats The burn treatment activity in humans described in Example 2 was demonstrated in animals.
The right hind leg of the rat was immersed in boiling water at 70 ° C. for 5 seconds, and the volume of swelling of the foot edema that appeared was measured. Specifically, a certain portion of the rat's right hind limb was marked using an oil-based black felt pen, immersed in a small aquarium up to the mark, and the amount (weight) of the rising water was measured. The measurement was performed before and 1, 3, and 5 hours after inflammation. FIG. 2 shows the results. As a result, a clear decrease was observed in the GL water group as compared with the control group (PBS group) 5 hours after the peak of the inflammation was considered. Since the same experiment was performed twice using three rats at each measurement point, six rats were used at each point in FIG. In addition, since the skin of the rat's foot is clearly thicker and harder than that of humans, the ability to promote the permeability of GL water to the skin and the permeability of other substances is more effective than that of humans. Is considered difficult to raise.
[0042]
Example 5: Therapeutic effect of GL water on herpes labialis When cold sores developed, GL water was sprayed onto the topical area early and tried at least 5 to 6 times. The herpes papules atrophy within the day, and the next day heals. By performing this local treatment, there were two or three cases in which systemic symptoms did not appear and recovered. In such cases, herpes papules and systemic symptoms disappear for several years. That is, there are cases in which it is considered that systemic symptoms have been completely cured by local therapy with GL water.
[0043]
The above-mentioned utility of GL water is presumed to be due to the comprehensive action of glycyrrhizin such as an anti-inflammatory action, an innate immunity-enhancing action, and an anti-viral action. Glycyrrhizin is known to cross mucosa. At that time, various antigenic substances present on the mucosal surface also stimulate and activate some nonspecific defense mechanisms of the living body as foreign substances entering the body together with glycyrrhizin, and nonspecifically prevent pathogens such as invading viruses and bacteria. You may be attacking.
[0044]
【The invention's effect】
The transdermal preparation of the present invention is useful as an agent for treating and / or preventing bruises, burns or pressure sores, and particularly useful as an aqueous transdermal preparation such as a spray, a gel, a lotion, and a poultice. is there.
[Brief description of the drawings]
FIG. 1 shows the results of an example in which a pressure sore was healed with GL water.
(1):
(3) 15 days of treatment: The surrounding granulation layer area was enlarged and the wound surface was dry.
(4) The 22nd day of treatment: The whole treatment process was less than one month, and healed rapidly. Spraying of the GL water was stopped after 25 days. This is because healing has been completed and there is no need for treatment.
(5) Treatment day 31: On the fourth day after the treatment was stopped, the pressure sore was completely healed.
FIG. 2 shows the therapeutic effect of GL water on burn edema in rats.
Claims (7)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003037553A JP2004262772A (en) | 2003-02-17 | 2003-02-17 | Glycyrrhizin-containing percutaneous pharmaceutical preparation |
| PCT/JP2004/001647 WO2004071516A1 (en) | 2003-02-17 | 2004-02-16 | Glycyrrhizine-containing percutaneous preparation |
| TW093103781A TW200418528A (en) | 2003-02-17 | 2004-02-17 | A glycyrrhizin containing percutaneous preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003037553A JP2004262772A (en) | 2003-02-17 | 2003-02-17 | Glycyrrhizin-containing percutaneous pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2004262772A true JP2004262772A (en) | 2004-09-24 |
Family
ID=32866367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003037553A Pending JP2004262772A (en) | 2003-02-17 | 2003-02-17 | Glycyrrhizin-containing percutaneous pharmaceutical preparation |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2004262772A (en) |
| TW (1) | TW200418528A (en) |
| WO (1) | WO2004071516A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007319051A (en) * | 2006-05-31 | 2007-12-13 | National Institute Of Advanced Industrial & Technology | Evaluation method of traditional Chinese medicine using gene expression profile |
| JP2012532831A (en) * | 2009-07-09 | 2012-12-20 | 株式会社ミノファーゲン製薬 | Glycyrrhizin as a restoring agent for the production of antimicrobial peptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09169652A (en) * | 1995-12-18 | 1997-06-30 | Lion Corp | Aqueous liquid composition |
| JPH11147826A (en) * | 1997-11-13 | 1999-06-02 | Lion Corp | Method for improving transdermal absorbability and external preparation for skin |
| JP2000109416A (en) * | 1998-10-02 | 2000-04-18 | Pola Chem Ind Inc | Cosmetic composition having antiobestic activity |
| JP2001097888A (en) * | 1999-09-28 | 2001-04-10 | Hiroshi Ikeno | Composition for external use |
-
2003
- 2003-02-17 JP JP2003037553A patent/JP2004262772A/en active Pending
-
2004
- 2004-02-16 WO PCT/JP2004/001647 patent/WO2004071516A1/en not_active Ceased
- 2004-02-17 TW TW093103781A patent/TW200418528A/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007319051A (en) * | 2006-05-31 | 2007-12-13 | National Institute Of Advanced Industrial & Technology | Evaluation method of traditional Chinese medicine using gene expression profile |
| JP2012532831A (en) * | 2009-07-09 | 2012-12-20 | 株式会社ミノファーゲン製薬 | Glycyrrhizin as a restoring agent for the production of antimicrobial peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004071516A1 (en) | 2004-08-26 |
| TW200418528A (en) | 2004-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105142728B (en) | Compositions and methods for treating surface wounds | |
| CN108853312B (en) | Polycinnamic alcohol external gel and preparation method thereof | |
| EP0112852A1 (en) | PHARMACEUTICAL GEL COMPOSITION. | |
| AU2004290463A1 (en) | Method and composition for treatment of cutaneous lesions | |
| JP2016503008A (en) | Compositions and methods for tissue regeneration | |
| US8409628B2 (en) | Methods and compositions for oxygenation of skin to treat skin disorders | |
| CN102600363B (en) | Traditional Chinese compound preparation for deep burnt wound restoration and tissue and skin regeneration promotion and preparation method of traditional Chinese compound preparation | |
| CN108186711A (en) | Promote the pharmaceutical composition of wound healing | |
| US11696907B2 (en) | Wound healing composition | |
| EP2692332B1 (en) | Composition for the treatment of callus, corns and psoriasis | |
| JP2004262772A (en) | Glycyrrhizin-containing percutaneous pharmaceutical preparation | |
| CN102631551A (en) | Compound Chinese medicine formulation as well as preparation method and application thereof | |
| ITMI941680A1 (en) | VEGETABLE EXTRACT AGAINST BURNS | |
| JPH05194214A (en) | Wound curing promoter | |
| Brocario et al. | Assessment of wound healing efficacy and tolerability using Cicatryl™ cream based on a suction blister model in healthy subjects | |
| ES2932359T3 (en) | Formulation based on N-acetylcysteine and urea for the treatment of dermatological disorders | |
| CN108635362B (en) | Pharmaceutical composition for treating diabetic foot | |
| CN106511676A (en) | Traditional Chinese medicine composition for treating bedsore in clinical nursing | |
| KR20100117864A (en) | Pharmaceutical composition for burn treatment | |
| CN1878560B (en) | Compositions containing Stryphnodendron extracts for topical use, methods for their preparation and use | |
| CA2325337C (en) | Use of live yeast cell derivative to treat bed sore pressure ulcers | |
| US20190000822A1 (en) | Chlorine or bromine salts of cetylpyridinium for use in the treatment of cutaneous and acute porphyrias and psoriasis | |
| AU6468800A (en) | Pharmaceutical composition for topical application, uses and process for the preparation thereof | |
| CN112741863A (en) | Medicine for treating skin wound and preparation method thereof | |
| CN115361964A (en) | Plant-based composition in a form suitable for topical application and related production method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090929 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100209 |